Jenthera Therapeutics
Jenthera discloses an in vivo autologous CAR-T reprogramming program in B-cell lymphoma using targeted ribonucleoprotein genome editing and homology-directed insertion. Website tumor-eradication statements do not establish human efficacy.
Corporate information
- Company entity
- Jenthera Therapeutics
- Headquarters / principal office
- Public offices in Saint-Laurent, Québec, and Toronto, CanadaThe website does not separately designate headquarters. ↗
- Founded
- 2019 ↗
- Ownership / capital status
- Not verifiedNot verified
- Official corporate reference
- https://www.jenthera.com/programs ↗
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Jenthera discloses an in vivo autologous CAR-T reprogramming program in B-cell lymphoma using targeted ribonucleoprotein genome editing and homology-directed insertion. Website tumor-eradication statements do not establish human efficacy.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- PROGRAMS | Jenthera
- Jenthera — official contact locations
- Founding / incorporation disclosure — scope stated in field